Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
PEGS Boston SummitPEGS Boston Summit
Not Confirmed
Not Confirmed
11 May-15 November, 2026
DIA Global Annual Meet...DIA Global Annual Meeting
Not Confirmed
Not Confirmed
14-18 June, 2026
Discovery EuropeDiscovery Europe
Not Confirmed
Not Confirmed
15-16 June, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
PEGS Boston Summit
Not Confirmed
Contact SupplierPEGS Boston Summit
PEGS Boston SummitPEGS Boston Summit
Industry Trade Show
Not Confirmed
11 May-15 November, 2026
DIA Global Annual Meet...DIA Global Annual Meeting
Industry Trade Show
Not Confirmed
14-18 June, 2026
Discovery EuropeDiscovery Europe
Industry Trade Show
Not Confirmed
15-16 June, 2026
Digital content
NEWS #PharmaBuzz
15 Oct 2025
// PHARMIWEB
https://www.pharmiweb.com/press-release/2025-10-15/adocia-and-tonghua-dongbao-announce-positive-topline-results-of-phase-3-clinical-trial-on-ultra-rapi
14 Oct 2021
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2021/10/14/2313915/0/en/Adocia-s-partner-Tonghua-Dongbao-Receives-Clearance-to-Start-Ultra-Rapid-Insulin-BioChaperone-Lispro-Phase-3-Trial-to-Treat-Type-1-and-Type-2-Diabetes-in-China.html
27 Apr 2018
// PHARMABIZ
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36695
Submission : 2022-02-16
Status : Active
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
NDC Package Code : 84934-001
Start Marketing Date : 2024-12-03
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
Drugs in Development
Details:
Insulin Lispro is a Hormone drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Diabetes Mellitus, Type 1.
Lead Product(s): Insulin Lispro,Insulin Glargine
Therapeutic Area: Endocrinology Brand Name: BioChaperone Lispro
Study Phase: Phase IIIProduct Type: Hormone
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 15, 2025
Lead Product(s) : Insulin Lispro,Insulin Glargine
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Insulin Lispro is a Hormone drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Diabetes Mellitus, Type 1.
Product Name : BioChaperone Lispro
Product Type : Hormone
Upfront Cash : Inapplicable
December 15, 2025
Details:
THDB0206 is a Hormone drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): THDB0206
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Hormone
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 02, 2025
Lead Product(s) : THDB0206
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparative PK/PD of Single-Dose THDB0206 at Different Injection Sites
Details : THDB0206 is a Hormone drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
December 02, 2025
Details:
Insulin Lispro, a peptide targeting the insulin receptor, shows promise in treating Type 1 Diabetes.
Lead Product(s): Insulin Lispro
Therapeutic Area: Endocrinology Brand Name: BioChaperone Lispro
Study Phase: Phase IIIProduct Type: Hormone
Recipient: Adocia
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 15, 2025
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Recipient : Adocia
Deal Size : Inapplicable
Deal Type : Inapplicable
Adocia, Tonghua Dongbao Report Positive Ph 3 Results for Ultra-Rapid Insulin
Details : Insulin Lispro, a peptide targeting the insulin receptor, shows promise in treating Type 1 Diabetes.
Product Name : BioChaperone Lispro
Product Type : Hormone
Upfront Cash : Inapplicable
October 15, 2025
Details:
THDBH120 is a drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Obesity.
Lead Product(s): THDBH120
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 25, 2025
Lead Product(s) : THDBH120
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase II Study of THDBH120 Injection in Overweight or Obese Subjects
Details : THDBH120 is a drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 25, 2025
Details:
THDBH120 is a drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.
Lead Product(s): THDBH120
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 13, 2025
Lead Product(s) : THDBH120
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
THDBH120 Safety, PK, and Efficacy In Chinese T2DM Patients
Details : THDBH120 is a drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 13, 2025
Details:
THDBH120 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Obesity.
Lead Product(s): THDBH120
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 30, 2025
Lead Product(s) : THDBH120
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : THDBH120 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 30, 2025
Details:
THDBH120 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): THDBH120
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 20, 2024
Lead Product(s) : THDBH120
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : THDBH120 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 20, 2024
Details:
Insulin Degludec is a Hormone drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus, Type 2.
Lead Product(s): Degludec,Liraglutide
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Hormone
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 19, 2024
Lead Product(s) : Degludec,Liraglutide
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Insulin Degludec is a Hormone drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
August 19, 2024
Details:
Insulin Degludec is a Hormone drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Degludec,Liraglutide
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Hormone
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 10, 2024
Lead Product(s) : Degludec,Liraglutide
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Insulin Degludec is a Hormone drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
June 10, 2024
Details:
THDB0206 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): THDB0206
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 01, 2023
Lead Product(s) : THDB0206
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : THDB0206 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 01, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Tonghua Dongbao Pharma is a supplier offers 2 products (APIs, Excipients or Intermediates).
Find Insulin Glargine bulk with DMF offered by Tonghua Dongbao Pharma
Find Liraglutide bulk offered by Tonghua Dongbao Pharma
Share 
